TTC28

tetratricopeptide repeat domain 28

Explore in graph →CI-GENE-00037394HGNC:29179 ENSG00000100154 NCBI 23331 Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TTC28 Fusion1
Futibatinib	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11645 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (13)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved13 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Schwannoma (Children's Tumor Foundation, Acta Neuropathologica 2020) schw_ctf_synodos_2025	Schwannoma	Ssm	7	40

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.